Table 1.
The efficacy endpoints of different therapy groups.
| BS group n = 81 | AG group n = 39 | AS group n = 38 | Total n = 158 | p | |
|---|---|---|---|---|---|
| Primary endpoints | |||||
| Successful PTAS, n (%) | 79 (97.5) | 35 (89.7) | 38 (100.0) | 152 (96.2) | 0.042 |
| Secondary endpoints | |||||
| Any stroke or death | 4 (4.9) | 0 (0.0) | 3 (7.9) | 7 (4.4) | 0.231 |
| Any ischemic stroke | 4 (4.9) | 0 (0.0) | 2 (5.3) | 6 (3.8) | 0.359 |
| Any hemorrhagic stroke | 0 (0.0) | 0 (0.0) | 1 (2.4) | 1 (0.6) | 0.204 |
| Death | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | – |
| MI | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | – |
| SAE | 0 (0.0) | 0 (0.0) | 1 (2.4) | 0 (0.6) | 0.204 |
| mRS ≥ 3 | 2 (2.5) | 0 (0.0) | 2 (5.3) | 4 (2.5) | 0.339 |
BS group, balloon-mounted stent group; AG group, angioplasty group; AS group, angioplasty plus self-expanding stent group; MI, myocardial infarction; mRS, modified Rankin scale; PTAS, percutaneous transluminal angioplasty and stenting; SAE, serious adverse even (28).